Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6076214 | 0.76 | SMN1; SMN2 (0.33) | KMT2ACYP3A4CYP2C19L3MBTL1MEN1 | |
| SCHEMBL6075644 | 0.75 | CYP3A4 (0.35) | KMT2ACYP3A4CYP2C19L3MBTL1MEN1 | |
| SCHEMBL5338371 | 0.70 | CYP3A4 (0.43) | CYP3A4CYP2C19L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL5341910 | 0.69 | MTNR1A (0.44) | CYP3A4CYP2C19L3MBTL1MTNR1A | |
| SCHEMBL6077215 | 0.69 | ALOX5 (0.43) | KMT2ACYP3A4CYP2C19L3MBTL1MEN1 | |
| SCHEMBL5344350 | 0.69 | MTNR1A (0.41) | CYP3A4CYP2C19L3MBTL1MTNR1A | |
| SCHEMBL7201684 | 0.68 | MTNR1A (0.59) | MTNR1AMTNR1B | |
| SCHEMBL6075940 | 0.63 | MTNR1A (0.36) | KMT2ACYP3A4CYP2C19L3MBTL1MEN1 | |
| SCHEMBL5351838 | 0.57 | ALOX5 (0.44) | MTNR1AMTNR1B | |
| SCHEMBL5336707 | 0.56 | ALOX5 (0.44) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183318-B2 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2007-02-27 | — | — | US | disclosed |
| US-20040002490-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | disclosed |
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | disclosed |
| US-6605632-B1 | Affinity for melatonin receptors | LES LABORATOIRES SERVIER (FR) | 2003-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | CYP4B1, CYP3A5, MC2R | KMT2A 3209/4885CYP3A4 14/4885CYP2C19 23/4885 |
| US-20040002490-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | CYP3A5, CYP4B1, MC2R | KMT2A 3174/4885CYP3A4 15/4885CYP2C19 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.